#BEGIN_DRUGCARD DB01240

# AHFS_Codes:
92:00.00

# ATC_Codes:
B01AC09

# Absorption:
Not Available

# Biotransformation:
Epoprostenol is metabolized to 2 primary metabolites: 6-keto-PGF1&alpha; (formed by spontaneous degradation) and 6,15-diketo-13,14-dihydro-PGF1&alpha; (enzymatically formed), both of which have pharmacological activity orders of magnitude less than epoprostenol in animal test systems. Fourteen additional minor metabolites have been isolated from urine, indicating that epoprostenol is extensively metabolized in humans.

# Brand_Mixtures:
Not Available

# Brand_Names:
Flolan

# CAS_Registry_Number:
35121-78-9

# ChEBI_ID:
15552

# Chemical_Formula:
C20H32O5

# Chemical_IUPAC_Name:
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-hexahydro-2H-cyclopenta[b]furan-2-ylidene]pentanoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2230845

# Description:
A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension.

# Dosage_Forms:
Injection, powder, for solution	Intravenous

# Drug_Category:
Antihypertensive Agents
Platelet Aggregation Inhibitors

# Drug_Interactions:
Trandolapril	The prostacyclin analogue, Epoprostenol, may increase the hypotensive effect of Trandolapril.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
3

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Epoprostenol

# HET_ID:
Not Available

# Half_Life:
The in vitro half-life of epoprostenol in human blood at 37&deg;C and pH 7.4 is approximately 6 minutes; the in vivo half-life of epoprostenol in humans is therefore expected to be no greater than 6 minutes.

# InChI_Identifier:
InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1

# InChI_Key:
InChIKey=KAQKFAOMNZTLHT-OZUDYXHBSA-N

# Indication:
For the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.

# KEGG_Compound_ID:
C01312

# KEGG_Drug_ID:
D00106

# LIMS_Drug_ID:
1240

# Mechanism_Of_Action:
Prostaglandins are present in most body tissues and fluids and mediate many biological functions. Epoprostenol (PGI2) is a member of the family of prostaglandins that is derived from arachidonic acid. The major pharmacological actions of epoprostenol is ultimately inhibition of platelet aggregation. Prostacyclin (PGI2) is released by healthy endothelial cells and performs its function through a paracrine signaling cascade that involves G protein-coupled receptors on nearby platelets and endothelial cells. The platelet Gs protein-coupled receptor (prostacyclin receptor) is activated when it binds to PGI2. This activation, in turn, signals adenylyl cyclase to produce cAMP. cAMP goes on to inhibit any undue platelet activation (in order to promote circulation) and also counteracts any increase in cytosolic calcium levels which would result from thromboxane A2 (TXA2) binding (leading to platelet activation and subsequent coagulation). PGI2 also binds to endothelial prostacyclin receptors and in the same manner raise cAMP levels in the cytosol. This cAMP then goes on to activate protein kinase A (PKA). PKA then continues the cascade by phosphorylating and inhibiting myosin light-chain kinase which leads to smooth muscle relaxation and vasodilation. Notably, PGI2 and TXA2 work as physiological antagonists.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
352.4651

# Molecular_Weight_Mono:
352.224974134

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA449479

# Pharmacology:
Epoprostenol has two major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds, and (2) inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. The effect of epoprostenol on heart rate in animals varies with dose. At low doses, there is vagally mediated brudycardia, but at higher doses, epoprostenol causes reflex tachycardia in response to direct vasodilation and hypotension. No major effects on cardiac conduction have been observed. Additional pharmacologic effects of epoprostenol in animals include bronchodilation, inhibition of gastric acid secretion, and decreased gastric emptying. No available chemical assay is sufficiently sensitive and specific to assess the in vivo human pharmacokinetics of epoprostenol.

# Predicted_LogP_Hydrophobicity:
3.83

# Predicted_LogS:
-3.4

# Predicted_Water_Solubility:
1.36e-01 g/l

# Primary_Accession_No:
DB01240

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5282411

# PubChem_Substance_ID:
46507362

# RxList_Link:
http://www.rxlist.com/cgi/generic/flolan.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00949

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])CC(O2)=CCCCC(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
PGI2
Prostacyclin
Prostaglandin I2

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of epoprostenol. Single intravenous doses at 10 and 50 mg/kg (2703 and 27,027 times the recommended acute phase human dose based on body surface area) were lethal to mice and rats, respectively. Symptoms of acute toxicity were hypoactivity, ataxia, loss of righting reflex, deep slow breathing, and hypothermia.

# Update_Date:
2013-02-08 16:20:02 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Epoprostenol

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP2C9

# Phase_1_Metabolizing_Enzyme_1_ID:
4757

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 2C9

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P11712

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
12297509	Yang J, Wu J, Jiang H, Mortensen R, Austin S, Manning DR, Woulfe D, Brass LF: Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors. J Biol Chem. 2002 Nov 29;277(48):46035-42. Epub 2002 Sep 23.
17155953	Cattaneo M, Lecchi A: Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost. 2007 Mar;5(3):577-82. Epub 2006 Dec 7.
20085435	Kobsar AL, Koessler J, Rajkovic MS, Brunner KP, Steigerwald U, Walter U: Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system. Platelets. 2010;21(2):112-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
P2RY12

# Drug_Target_1_GenBank_ID_Gene:
AF313449

# Drug_Target_1_GenBank_ID_Protein:
12083902

# Drug_Target_1_GeneCard_ID:
P2RY12

# Drug_Target_1_Gene_Name:
P2RY12

# Drug_Target_1_Gene_Sequence:
>1029 bp
ATGCAAGCCGTCGACAACCTCACCTCTGCGCCTGGGAACACCAGTCTGTGCACCAGAGAC
TACAAAATCACCCAGGTCCTCTTCCCACTGCTCTACACTGTCCTGTTTTTTGTTGGACTT
ATCACAAATGGCCTGGCGATGAGGATTTTCTTTCAAATCCGGAGTAAATCAAACTTTATT
ATTTTTCTTAAGAACACAGTCATTTCTGATCTTCTCATGATTCTGACTTTTCCATTCAAA
ATTCTTAGTGATGCCAAACTGGGAACAGGACCACTGAGAACTTTTGTGTGTCAAGTTACC
TCCGTCATATTTTATTTCACAATGTATATCAGTATTTCATTCCTGGGACTGATAACTATC
GATCGCTACCAGAAGACCACCAGGCCATTTAAAACATCCAACCCCAAAAATCTCTTGGGG
GCTAAGATTCTCTCTGTTGTCATCTGGGCATTCATGTTCTTACTCTCTTTGCCTAACATG
ATTCTGACCAACAGGCAGCCGAGAGACAAGAATGTGAAGAAATGCTCTTTCCTTAAATCA
GAGTTCGGTCTAGTCTGGCATGAAATAGTAAATTACATCTGTCAAGTCATTTTCTGGATT
AATTTCTTAATTGTTATTGTATGTTATACACTCATTACAAAAGAACTGTACCGGTCATAC
GTAAGAACGAGGGGTGTAGGTAAAGTCCCCAGGAAAAAGGTGAACGTCAAAGTTTTCATT
ATCATTGCTGTATTCTTTATTTGTTTTGTTCCTTTCCATTTTGCCCGAATTCCTTACACC
CTGAGCCAAACCCGGGATGTCTTTGACTGCACTGCTGAAAATACTCTGTTCTATGTGAAA
GAGAGCACTCTGTGGTTAACTTCCTTAAATGCATGCCTGGATCCGTTCATCTATTTTTTC
CTTTGCAAGTCCTTCAGAAATTCCTTGATAAGTATGCTGAAGTGCCCCAATTCTGCAACA
TCTCTGTCCCAGGACAATAGGAAAAAAGAACAGGATGGTGGTGACCCAAATGAAGAGACT
CCAATGTAA

# Drug_Target_1_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_1_General_References:
11104774	Zhang FL, Luo L, Gustafson E, Lachowicz J, Smith M, Qiao X, Liu YH, Chen G, Pramanik B, Laz TM, Palmer K, Bayne M, Monsma FJ Jr: ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. J Biol Chem. 2001 Mar 16;276(11):8608-15. Epub 2000 Dec 4.
11196645	Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001 Jan 11;409(6817):202-7.
11502873	Takasaki J, Kamohara M, Saito T, Matsumoto M, Matsumoto S, Ohishi T, Soga T, Matsushime H, Furuichi K: Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol. 2001 Sep;60(3):432-9.
12044878	Takeda S, Kadowaki S, Haga T, Takaesu H, Mitaku S: Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett. 2002 Jun 5;520(1-3):97-101.

# Drug_Target_1_HGNC_ID:
HGNC:18124

# Drug_Target_1_HPRD_ID:
02743

# Drug_Target_1_ID:
122

# Drug_Target_1_Locus:
3q24-q25

# Drug_Target_1_Molecular_Weight:
39439

# Drug_Target_1_Name:
P2Y purinoceptor 12

# Drug_Target_1_Number_of_Residues:
342

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Abciximab Pathway	SMP00265
Acetylsalicylic Acid Pathway	SMP00083
Celecoxib Pathway	SMP00096
Cilostazol Pathway	SMP00263
Clopidogrel Pathway	SMP00260
Dipyridamole (Antiplatelet) Pathway	SMP00264
Eptifibatide Pathway	SMP00266
Etodolac Pathway	SMP00084
Meloxicam Pathway	SMP00106
Rofecoxib Pathway	SMP00087
Ticlopidine Pathway	SMP00261
Tirofiban Pathway	SMP00267
Valdecoxib Pathway	SMP00116

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>P2Y purinoceptor 12
MQAVDNLTSAPGNTSLCTRDYKITQVLFPLLYTVLFFVGLITNGLAMRIFFQIRSKSNFI
IFLKNTVISDLLMILTFPFKILSDAKLGTGPLRTFVCQVTSVIFYFTMYISISFLGLITI
DRYQKTTRPFKTSNPKNLLGAKILSVVIWAFMFLLSLPNMILTNRQPRDKNVKKCSFLKS
EFGLVWHEIVNYICQVIFWINFLIVIVCYTLITKELYRSYVRTRGVGKVPRKKVNVKVFI
IIAVFFICFVPFHFARIPYTLSQTRDVFDCTAENTLFYVKESTLWLTSLNACLDPFIYFF
LCKSFRNSLISMLKCPNSATSLSQDNRKKEQDGGDPNEETPM

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Involved in platelets aggregation

# Drug_Target_1_SwissProt_ID:
Q9H244

# Drug_Target_1_SwissProt_Name:
P2Y12_HUMAN

# Drug_Target_1_Synonyms:
ADP-glucose receptor
ADPG-R
P2T(AC)
P2Y(AC)
P2Y(ADP)
P2Y(cyc)
P2Y12
P2Y12 platelet ADP receptor
SP1999

# Drug_Target_1_Theoretical_pI:
9.99

# Drug_Target_1_Transmembrane_Regions:
26-46
59-79
100-120
143-163
192-212
234-254
282-302

# Drug_Target_2_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
12297509	Yang J, Wu J, Jiang H, Mortensen R, Austin S, Manning DR, Woulfe D, Brass LF: Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors. J Biol Chem. 2002 Nov 29;277(48):46035-42. Epub 2002 Sep 23.
19302827	Kasza Z, Fetalvero KM, Ding M, Wagner RJ, Acs K, Guzman AK, Douville KL, Powell RJ, Hwa J, Martin KA: Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. J Mol Cell Cardiol. 2009 May;46(5):682-94. Epub 2009 Jan 23.
20522800	Ibrahim S, Tetruashvily M, Frey AJ, Wilson SJ, Stitham J, Hwa J, Smyth EM: Dominant negative actions of human prostacyclin receptor variant through dimerization: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1802-9. Epub 2010 Jun 3.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
PTGIR

# Drug_Target_2_GenBank_ID_Gene:
L29016

# Drug_Target_2_GenBank_ID_Protein:
495043

# Drug_Target_2_GeneCard_ID:
PTGIR

# Drug_Target_2_Gene_Name:
PTGIR

# Drug_Target_2_Gene_Sequence:
>1161 bp
ATGGCGGATTCGTGCAGGAACCTCACCTACGTGCGGGGCTCGGTGGGGCCGGCCACCAGC
ACCCTGATGTTCGTGGCCGGTGTGGTGGGCAACGGGCTGGCCCTGGGCATCCTGAGCGCA
CGGCGACCGGCGCGCCCCTCGGCCTTCGCGGTGCTGGTCACCGGACTGGCGGCCACCGAC
CTGCTGGGCACCAGCTTCCTGAGCCCGGCCGTGTTCGTGGCCTATGCGCGCAACAGCTCC
CTGCTGGGCCTGGCCCGAGGCGGCCCCGCCCTGTGCGATGCCTTCGCCTTCGCCATGACC
TTCTTCGGCCTGGCGTCCATGCTCATCCTCTTTGCCATGGCCGTGGAGCGCTGCCTGGCG
CTGAGCCACCCCTACCTCTACGCGCAGCTGGACGGGCCCCGCTGCGCCCGCCTGGCGCTG
CCAGCCATCTACGCCTTCTGCGTCCTCTTCTGCGCGCTGCCCCTGCTGGGCCTGGGCCAA
CACCAGCAGTACTGCCCCGGCAGCTGGTGCTTCCTCCGCATGCGCTGGGCCCAGCCGGGC
GGCGCCGCCTTCTCGCTGGCCTACGCCGGCCTGGTGGCCCTGCTGGTGGCTGCCATCTTC
CTCTGCAACGGCTCGGTCACCCTCAGCCTCTGCCGCATGTACCGCCAGCAGAAGCGCCAC
CAGGGCTCTCTGGGTCCACGGCCGCGCACCGGAGAGGACGAGGTGGACCACCTGATCCTG
CTGGCCCTCATGACAGTGGTCATGGCCGTGTGCTCCCTGCCTCTCACGATCCGCTGCTTC
ACCCAGGCTGTCGCCCCTGACAGCAGCAGTGAGATGGGGGACCTCCTTGCCTTCCGCTTC
TACGCCTTCAACCCCATCCTGGACCCCTGGGTCTTCATCCTTTTCCGCAAGGCTGTCTTC
CAGCGACTCAAGCTCTGGGTCTGCTGCCTGTGCCTCGGGCCTGCCCACGGAGACTCGCAG
ACACCCCTTTCCCAGCTCGCCTCCGGGAGGAGGGACCCAAGGGCCCCCTCTGCTCCTGTG
GGAAAGGAGGGGAGCTGCGTGCCTTTGTCGGCTTGGGGCGAGGGGCAGGTGGAGCCCTTG
CCTCCCACACAGCAGTCCAGCGGCAGCGCCGTGGGAACGTCGTCCAAAGCAGAAGCCAGC
GTCGCCTGCTCCCTCTGCTGA

# Drug_Target_2_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_2_General_References:
12488443	Miggin SM, Lawler OA, Kinsella BT: Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58. Epub 2002 Dec 17.
7512962	Boie Y, Rushmore TH, Darmon-Goodwin A, Grygorczyk R, Slipetz DM, Metters KM, Abramovitz M: Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem. 1994 Apr 22;269(16):12173-8.
7514139	Katsuyama M, Sugimoto Y, Namba T, Irie A, Negishi M, Narumiya S, Ichikawa A: Cloning and expression of a cDNA for the human prostacyclin receptor. FEBS Lett. 1994 May 9;344(1):74-8.
7665161	Ogawa Y, Tanaka I, Inoue M, Yoshitake Y, Isse N, Nakagawa O, Usui T, Itoh H, Yoshimasa T, Narumiya S, et al.: Structural organization and chromosomal assignment of the human prostacyclin receptor gene. Genomics. 1995 May 1;27(1):142-8.
7923647	Nakagawa O, Tanaka I, Usui T, Harada M, Sasaki Y, Itoh H, Yoshimasa T, Namba T, Narumiya S, Nakao K: Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation. 1994 Oct;90(4):1643-7.

# Drug_Target_2_HGNC_ID:
HGNC:9602

# Drug_Target_2_HPRD_ID:
08959

# Drug_Target_2_ID:
527

# Drug_Target_2_Locus:
19q13.3

# Drug_Target_2_Molecular_Weight:
40956

# Drug_Target_2_Name:
Prostacyclin receptor

# Drug_Target_2_Number_of_Residues:
386

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Celecoxib Pathway	SMP00096
Etodolac Pathway	SMP00084
Meloxicam Pathway	SMP00106
Rofecoxib Pathway	SMP00087
Valdecoxib Pathway	SMP00116

# Drug_Target_2_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_2_Protein_Sequence:
>Prostacyclin receptor
MADSCRNLTYVRGSVGPATSTLMFVAGVVGNGLALGILSARRPARPSAFAVLVTGLAATD
LLGTSFLSPAVFVAYARNSSLLGLARGGPALCDAFAFAMTFFGLASMLILFAMAVERCLA
LSHPYLYAQLDGPRCARLALPAIYAFCVLFCALPLLGLGQHQQYCPGSWCFLRMRWAQPG
GAAFSLAYAGLVALLVAAIFLCNGSVTLSLCRMYRQQKRHQGSLGPRPRTGEDEVDHLIL
LALMTVVMAVCSLPLTIRCFTQAVAPDSSSEMGDLLAFRFYAFNPILDPWVFILFRKAVF
QRLKLWVCCLCLGPAHGDSQTPLSQLASGRRDPRAPSAPVGKEGSCVPLSAWGEGQVEPL
PPTQQSSGSAVGTSSKAEASVACSLC

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase

# Drug_Target_2_SwissProt_ID:
P43119

# Drug_Target_2_SwissProt_Name:
PI2R_HUMAN

# Drug_Target_2_Synonyms:
PGI receptor
Prostaglandin I2 receptor
Prostanoid IP receptor

# Drug_Target_2_Theoretical_pI:
8.53

# Drug_Target_2_Transmembrane_Regions:
17-38
52-76
95-115
135-158
182-208
236-260
275-295

# Drug_Target_3_Cellular_Location:
Endoplasmic reticulum
endoplasmic reticulum membrane
single-pass membrane protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
18081314	Ruan KH, Wu J, Cervantes V: Characterization of the substrate mimic bound to engineered prostacyclin synthase in solution using high-resolution NMR spectroscopy and mutagenesis: implication of the molecular mechanism in biosynthesis of prostacyclin. Biochemistry. 2008 Jan 15;47(2):680-8. Epub 2007 Dec 15.
20357747	Nakayama T: Genetic polymorphisms of prostacyclin synthase gene and cardiovascular disease. Int Angiol. 2010 Apr;29(2 Suppl):33-42.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
PTGIS

# Drug_Target_3_GenBank_ID_Gene:
D38145

# Drug_Target_3_GenBank_ID_Protein:
10944956

# Drug_Target_3_GeneCard_ID:
PTGIS

# Drug_Target_3_Gene_Name:
PTGIS

# Drug_Target_3_Gene_Sequence:
>1503 bp
ATGGCTTGGGCCGCGCTCCTCGGCCTCCTGGCCGCACTGTTGCTGCTGCTGCTACTGAGC
CGCCGCCGCACGCGGCGACCTGGTGAGCCTCCCCTGGACCTGGGCAGCATCCCCTGGTTG
GGGTATGCCTTGGACTTTGGAAAAGATGCTGCCAGCTTCCTCACGAGGATGAAGGAGAAG
CACGGTGACATCTTTACTATACTGGTTGGGGGCAGGTATGTCACCGTTCTCCTGGACCCA
CACTCCTACGACGCGGTGGTGTGGGAGCCTCGCACCAGGCTCGACTTCCATGCCTATGCC
ATCTTCCTCATGGAGAGGATTTTTGATGTGCAGCTTCCACATTACAGCCCCAGTGATGAA
AAGGCCAGGATGAAACTGACTCTTCTCCACAGAGAGCTCCAGGCACTCACAGAAGCCATG
TATACCAACCTCCATGCAGTGCTGTTGGGCGATGCTACAGAAGCAGGCAGTGGCTGGCAC
GAGATGGGTCTCCTCGACTTCTCCTACAGCTTCCTGCTCAGAGCCGGCTACCTGACTCTT
TACGGAATTGAGGCGCTGCCACGCACCCATGAAAGCCAGGCCCAGGACCGCGTCCACTCA
GCTGATGTCTTCCACACCTTTCGCCAGCTCGACCGGCTGCTCCCCAAACTGGCCCGTGGC
TCCCTGTCAGTGGGGGACAAGGACCACATGTGCAGTGTCAAAAGTCGCCTGTGGAAGCTG
CTATCCCCAGCCAGGCTGGCCAGGCGGGCCCACCGGAGCAAATGGCTGGAGAGTTACCTG
CTGCACCTGGAGGAGATGGGTGTGTCAGAGGAGATGCAGGCACGGGCCCTGGTGCTGCAG
CTGTGGGCCACACAGGGGAATATGGGTCCCGCTGCCTTCTGGCTCCTGCTCTTCCTTCTC
AAGAATCCTGAAGCCCTGGCTGCTGTCCGCGGAGAGCTCGAGAGTATCCTTTGGCAAGCG
GAGCAGCCTGTCTCGCAGACGACCACTCTCCCACAGAAGGTTCTAGACAGCACACCTGTG
CTTGATAGCGTGCTGAGTGAGAGCCTCAGGCTTACAGCTGCCCCCTTCATCACCCGCGAG
GTTGTGGTGGACCTGGCCATGCCCATGGCAGACGGGAGAGAATTCAACCTGCGACGTGGT
GACCGCCTCCTCCTCTTCCCCTTCCTGAGCCCCCAGAGAGACCCAGAAATCTACACAGAC
CCAGAGGTATTTAAATACAACCGATTCCTGAACCCTGACGGATCAGAGAAGAAAGACTTT
TACAAGGATGGGAAACGGCTGAAGAATTACAACATGCCCTGGGGGGCGGGGCACAATCAC
TGCCTGGGGAGGAGTTATGCGGTCAACAGCATCAAACAATTTGTGTTCCTTGTGCTGGTG
CACTTGGACTTGGAGCTGATCAACGCAGATGTGGAGATCCCTGAGTTTGACCTCAGCAGG
TACGGCTTCGGTCTGATGCAGCCGGAACACGACGTGCCCGTCCGCTACCGCATCCGCCCA
TGA

# Drug_Target_3_General_Function:
Secondary metabolites biosynthesis, transport and catabolism

# Drug_Target_3_General_References:
11281454	Chevalier D, Cauffiez C, Bernard C, Lo-Guidice JM, Allorge D, Fazio F, Ferrari N, Libersa C, Lhermitte M, D'Halluin JC, Broly F: Characterization of new mutations in the coding sequence and 5'-untranslated region of the human prostacylcin synthase gene (CYP8A1). Hum Genet. 2001 Feb;108(2):148-55.
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
8185632	Miyata A, Hara S, Yokoyama C, Inoue H, Ullrich V, Tanabe T: Molecular cloning and expression of human prostacyclin synthase. Biochem Biophys Res Commun. 1994 May 16;200(3):1728-34.

# Drug_Target_3_HGNC_ID:
HGNC:9603

# Drug_Target_3_HPRD_ID:
09046

# Drug_Target_3_ID:
130

# Drug_Target_3_Locus:
20q13.13

# Drug_Target_3_Molecular_Weight:
57105

# Drug_Target_3_Name:
Prostacyclin synthase

# Drug_Target_3_Number_of_Residues:
500

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Acetylsalicylic Acid Pathway	SMP00083
Bromfenac Pathway	SMP00102
Celecoxib Pathway	SMP00096
Diclofenac Pathway	SMP00093
Diflunisal Pathway	SMP00289
Etodolac Pathway	SMP00084
Ibuprofen Pathway	SMP00086
Indomethacin Pathway	SMP00104
Ketoprofen Pathway	SMP00085
Ketorolac Pathway	SMP00098
Mefanamic Acid Pathway	SMP00109
Meloxicam Pathway	SMP00106
Nabumetone Pathway	SMP00114
Naproxen Pathway	SMP00120
Oxaprozin Pathway	SMP00113
Piroxicam Pathway	SMP00077
Rofecoxib Pathway	SMP00087
Sulindac Pathway	SMP00094
Suprofen Pathway	SMP00101
Valdecoxib Pathway	SMP00116

# Drug_Target_3_Pfam_Domain_Function:
PF00067	p450

# Drug_Target_3_Protein_Sequence:
>Prostacyclin synthase
MAWAALLGLLAALLLLLLLSRRRTRRPGEPPLDLGSIPWLGYALDFGKDAASFLTRMKEK
HGDIFTILVGGRYVTVLLDPHSYDAVVWEPRTRLDFHAYAIFLMERIFDVQLPHYSPSDE
KARMKLTLLHRELQALTEAMYTNLHAVLLGDATEAGSGWHEMGLLDFSYSFLLRAGYLTL
YGIEALPRTHESQAQDRVHSADVFHTFRQLDRLLPKLARGSLSVGDKDHMCSVKSRLWKL
LSPARLARRAHRSKWLESYLLHLEEMGVSEEMQARALVLQLWATQGNMGPAAFWLLLFLL
KNPEALAAVRGELESILWQAEQPVSQTTTLPQKVLDSTPVLDSVLSESLRLTAAPFITRE
VVVDLAMPMADGREFNLRRGDRLLLFPFLSPQRDPEIYTDPEVFKYNRFLNPDGSEKKDF
YKDGKRLKNYNMPWGAGHNHCLGRSYAVNSIKQFVFLVLVHLDLELINADVEIPEFDLSR
YGFGLMQPEHDVPVRYRIRP

# Drug_Target_3_Reaction:
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13- dienoate = (5Z,13E)-(15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13- dienoate

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Catalyzes the isomerization of prostaglandin H2 to prostacyclin (= prostaglandin I2)

# Drug_Target_3_SwissProt_ID:
Q16647

# Drug_Target_3_SwissProt_Name:
PTGIS_HUMAN

# Drug_Target_3_Synonyms:
EC 5.3.99.4
Prostaglandin I2 synthase

# Drug_Target_3_Theoretical_pI:
7.33

# Drug_Target_3_Transmembrane_Regions:
1-20

#END_DRUGCARD DB01240
